Stock Events

Stock Events

Evolus 

$8.60
41
+$0.00+0% 09:00 Today

Statistics

Day High
8.61
Day Low
8.33
52W High
8.69
52W Low
3.86
Volume
24,305
Avg. Volume
-
Mkt Cap
568.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.25
-0.15
-0.06
0.03
Expected EPS
-0.07225
Actual EPS
N/A

Financials

-17.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
297.18MRevenue
-51.64MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 13.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EOLS. It's not an investment recommendation.
Tesla
9
TSLA
Amazon
9
AMZN
NVIDIA
8
NVDA
Apple
7
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap335.14B
Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.
GSK
GSK
Mkt Cap99.18B
GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.
Pfizer
PFE
Mkt Cap152.69B
Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.
State Street Global Allocation
GAL
Mkt Cap0
Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.
Revolve Group
RVLV
Mkt Cap1.68B
Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.85B
Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.
Novartis
NVS
Mkt Cap286.78B
Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

About

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Show more...
CEO
David Moatazedi
Employees
353
Country
United States
ISIN
US30052C1071
WKN
000A2JDYX

Listings

LSE
GB
0K16.LSE
STU
DE
EVL.STU
BOATS
BOATS
EOLS.BOATS
MU
DE
EVL.MU

0 Comments

Share your thoughts

FAQ

What is Evolus stock price today?▼
The current price of EOLS is $8.60 USD — it has increased by +0% in the past 24 hours. Watch Evolus stock price performance more closely on the chart.
What is Evolus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Evolus stocks are traded under the ticker EOLS.
Is Evolus stock price growing?▼
EOLS stock has risen by +7.23% compared to the previous week, the month change is a +55.09% rise, over the last year Evolus has showed a +18.95% increase.
What is Evolus market cap?▼
Today Evolus has the market capitalization of 568.03M
When is the next Evolus earnings date?▼
Evolus is going to release the next earnings report on November 10, 2026.
What were Evolus earnings last quarter?▼
EOLS earnings for the last quarter are 0.01 USD per share, whereas the estimation was -0.03 USD resulting in a +122.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Evolus revenue for the last year?▼
Evolus revenue for the last year amounts to 297.18M USD.
What is Evolus net income for the last year?▼
EOLS net income for the last year is -51.64M USD.
How many employees does Evolus have?▼
As of August 20, 2026, the company has 353 employees.
In which sector is Evolus located?▼
Evolus operates in the Health & Wellness sector.
When did Evolus complete a stock split?▼
Evolus has not had any recent stock splits.
Where is Evolus headquartered?▼
Evolus is headquartered in NEWPORT BEACH, United States.